|
1
|
Nilsson B, Bümming P, Meis-Kindblom JM,
Odén A, Dortok A, Gustavsson B, Sablinska K and Kindblom LG:
Gastrointestinal stromal tumors: The incidence, prevalence,
clinical course, and prognostication in the preimatinib mesylate
era-a population-based study in western Sweden. Cancer.
103:821–829. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Miettinen M and Lasota J: Gastrointestinal
stromal tumors: Pathology and prognosis at different sites. Semin
Diagn Pathol. 23:70–83. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hirota S, Isozaki K, Moriyama Y, Hashimoto
K, Nishida T, Ishiguro S, Kawano K, Hanada M, Kurata A, Takeda M,
et al: Gain-of-function mutations of c-kit in human
gastrointestinal stromal tumors. Science. 279:577–580. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heinrich MC, Corless CL, Duensing A,
McGreevey L, Chen CJ, Joseph N, Singer S, Griffith DJ, Haley A,
Town A, et al: PDGFRA activating mutations in gastrointestinal
stromal tumors. Science. 299:708–710. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Casali PG, Abecassis N, Bauer S, Biagini
R, Bielack S, Bonvalot S, Boukovinas I, Bovee JVMG, Brodowicz T,
Broto JM, et al: Gastrointestinal stromal tumours: ESMO-EURACAN
clinical practice guidelines for diagnosis, treatment and
follow-up. Ann Oncol. 29:iv68–iv78. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Van Glabbeke M, Verweij J, Casali PG, Le
Cesne A, Hohenberger P, Ray-Coquard I, Schlemmer M, van Oosterom
AT, Goldstein D, Sciot R, et al: Initial and late resistance to
imatinib in advanced gastrointestinal stromal tumors are predicted
by different prognostic factors: A european organisation for
research and treatment of cancer-italian sarcoma group-australasian
gastrointestinal trials group study. J Clin Oncol. 23:5795–5804.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Demetri GD, van Oosterom AT, Garrett CR,
Blackstein ME, Shah MH, Verweij J, McArthur G, Judson IR, Heinrich
MC, Morgan JA, et al: Efficacy and safety of sunitinib in patients
with advanced gastrointestinal stromal tumour after failure of
imatinib: A randomised controlled trial. Lancet. 368:1329–1338.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Joensuu H, Wardelmann E, Sihto H, Eriksson
M, Sundby Hall K, Reichardt A, Hartmann JT, Pink D, Cameron S,
Hohenberger P, et al: Effect of KIT and PDGFRA mutations on
survival in patients with gastrointestinal stromal tumors treated
with adjuvant imatinib: An exploratory analysis of a randomized
clinical trial. JAMA Oncol. 3:602–609. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Farag S, Somaiah N, Choi H, Heeres B, Wang
WL, van Boven H, Nederlof P, Benjamin R, van der Graaf W, Grunhagen
D, et al: Clinical characteristics and treatment outcome in a large
multicentre observational cohort of PDGFRA exon 18 mutated
gastrointestinal stromal tumour patients. Eur J Cancer. 76:76–83.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Rutkowski P, Bylina E, Klimczak A, Switaj
T, Falkowski S, Kroc J, Lugowska I, Brzeskwiniewicz M, Melerowicz
W, Osuch C, et al: The outcome and predictive factors of sunitinib
therapy in advanced gastrointestinal stromal tumors (GIST) after
imatinib failure-one institution study. BMC Cancer. 12:1072012.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Heinrich MC, Maki RG, Corless CL,
Antonescu CR, Harlow A, Griffith D, Town A, McKinley A, Ou WB,
Fletcher JA, et al: Primary and secondary kinase genotypes
correlate with the biological and clinical activity of sunitinib in
imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol.
26:5352–5359. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, Dancey J, Arbuck S, Gwyther S,
Mooney M, et al: New response evaluation criteria in solid tumours:
revised RECIST guideline (version 1.1). Eur J Cancer. 45:228–247.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Liu G, Ke LC and Sun SR: Prognostic value
of pretreatment neutrophil-to-lymphocyte ratio in patients with
soft tissue sarcoma: A meta-analysis. Medicine (Baltimore).
97:e121762018. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mei Z, Shi L, Wang B, Yang J, Xiao Z, Du
P, Wang Q and Yang W: Prognostic role of pretreatment blood
neutrophil-to-lymphocyte ratio in advanced cancer survivors: A
systematic review and meta-analysis of 66 cohort studies. Cancer
Treat Rev. 58:1–13. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Templeton AJ, McNamara MG, Šeruga B,
Vera-Badillo FE, Aneja P, Ocaña A, Leibowitz-Amit R, Sonpavde G,
Knox JJ, Tran B, et al: Prognostic role of neutrophil-to-lymphocyte
ratio in solid tumors: A systematic review and meta-analysis. J
Natl Cancer Inst. 106:dju1242014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guthrie GJ, Charles KA, Roxburgh CS,
Horgan PG, McMillan DC and Clarke SJ: The systemic
inflammation-based neutrophil-lymphocyte ratio: Experience in
patients with cancer. Crit Rev Oncol Hematol. 88:218–230. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Goh BK, Chok AY, Allen JC Jr, Quek R, Teo
MC, Chow PK, Chung AY, Ong HS and Wong WK: Blood neutrophil-to-
lymphocyte and platelet-to-lymphocyte ratios are independent
prognostic factors for surgically resected gastrointestinal stromal
tumors. Surgery. 159:1146–1156. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Stotz M, Liegl-Atzwanger B, Posch F, Mrsic
E, Thalhammer M, Stojakovic T, Bezan A, Pichler M, Gerger A and
Szkandera J: Blood-based biomarkers are associated with disease
recurrence and survival in gastrointestinal stroma tumor patients
after surgical resection. PLoS One. 11:e01594482016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Perez DR, Baser RE, Cavnar MJ,
Balachandran VP, Antonescu CR, Tap WD, Strong VE, Brennan MF, Coit
DG, Singer S and Dematteo RP: Blood neutrophil-to-lymphocyte ratio
is prognostic in gastrointestinal stromal tumor. Ann Surg Oncol.
20:593–599. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jiang C, Hu WM, Liao FX, Yang Q, Chen P,
Rong YM, Guo GF, Yin CX, Zhang B, He WZ and Xia LP: Elevated
preoperative neutrophil-to-lymphocyte ratio is associated with poor
prognosis in gastrointestinal stromal tumor patients. OncoTargets
Ther. 9:877–883. 2016. View Article : Google Scholar
|
|
21
|
Racz JM, Cleghorn MC, Jimenez MC, Atenafu
EG, Jackson TD, Okrainec A, Venkat Raghavan L and Quereshy FA:
Predictive ability of blood neutrophil-to-lymphocyte and
platelet-to-lymphocyte ratios in gastrointestinal stromal tumors.
Ann Surg Oncol. 22:2343–2350. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hanahan D and Weinberg RA: Hallmarks of
cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galdiero MR, Bonavita E, Barajon I,
Garlanda C, Mantovani A and Jaillon S: Tumor associated macrophages
and neutrophils in cancer. Immunobiology. 218:1402–1410. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Petrie HT, Klassen LW and Kay HD:
Inhibition of human cytotoxic T lymphocyte activity in vitro by
autologous peripheral blood granulocytes. J Immunol. 134:230–234.
1985.PubMed/NCBI
|
|
25
|
Dumitru CA, Lang S and Brandau S:
Modulation of neutrophil granulocytes in the tumor
microenvironment: Mechanisms and consequences for tumor
progression. Semin Cancer Biol. 23:141–148. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Motomura T, Shirabe K, Mano Y, Muto J,
Toshima T, Umemoto Y, Fukuhara T, Uchiyama H, Ikegami T, Yoshizumi
T, et al: Neutrophil-lymphocyte ratio reflects hepatocellular
carcinoma recurrence after liver transplantation via inflammatory
microenvironment. J Hepatol. 58:58–64. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kantola T, Klintrup K, Väyrynen JP,
Vornanen J, Bloigu R, Karhu T, Herzig KH, Näpänkangas J, Mäkelä J,
Karttunen TJ, et al: Stage-dependent alterations of the serum
cytokine pattern in colorectal carcinoma. Br J Cancer.
107:1729–1736. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Elliott RL and Blobe GC: Role of
transforming growth factor Beta in human cancer. J Clin Oncol.
23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yang L, Pang Y and Moses HL: TGF-beta and
immune cells: An important regulatory axis in the tumor
microenvironment and progression. Trends Immunology. 31:220–227.
2010. View Article : Google Scholar
|
|
30
|
Wardelmann E, Merkelbach-Bruse S, Pauls K,
Thomas N, Schildhaus HU, Heinicke T, Speidel N, Pietsch T, Buettner
R, Pink D, et al: Polyclonal evolution of multiple secondary KIT
mutations in gastrointestinal stromal tumors under treatment with
imatinib mesylate. Clin Cancer Res. 12:1743–1749. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Proctor MJ, Morrison DS, Talwar D, Balmer
SM, Fletcher CD, O'Reilly DS, Foulis AK, Horgan PG and McMillan DC:
A comparison of inflammation-based prognostic scores in patients
with cancer. A glasgow inflammation outcome study. Eur J Cancer.
47:2633–2641. 2011. View Article : Google Scholar : PubMed/NCBI
|
